印度Lupin公司正在商谈如何用10亿英镑购买英国营养品公司维他命生物。 Indian firm Lupin is in talks to buy UK nutraceutical company Vitabiotics for £1 billion.

印度制药商Lupin与私人股权公司TPG资本和EQT伙伴进行早期会谈,以可能获得以英国为基地的营养品公司Vitavicences,价值约10亿英镑。 Indian drugmaker Lupin is in early talks with private equity firms TPG Capital and EQT Partners to potentially acquire UK-based nutraceutical company Vitabiotics, valued at around £1 billion. 这笔交易可能涉及财团投标,随着印度制药公司在全球扩张,对快速增长的印度营养品市场的投资不断增长,这一交易就出现了。 The deal, which could involve a consortium bid, comes as Indian pharma firms expand globally amid rising investment in the fast-growing Indian nutraceuticals market. 虽然人类制药公司和Zydus Wellness公司以前由于估值高而退步,但Lupin公司在2025年进行了其他国际收购活动。 While Mankind Pharma and Zydus Wellness previously stepped back due to high valuations, Lupin has pursued other international acquisitions in 2025. 维塔生物制品以Pregnacare和Wellwoman等品牌而闻名, 通过印度分支公司, 产生的每年253万英销售额约占其年销售额的20%, Vitabiotics, known for brands like Pregnacare and Wellwoman, generates about 20% of its £253 million annual sales through its Indian arm, where prescription sales rose 13% year-on-year. 该公司在Houlihan Lokey的咨询下,正在积极寻找买家,Unilever和Nestlé也报告对此有兴趣。 The company is actively seeking buyers, advised by Houlihan Lokey, with interest also reported from Unilever and Nestlé. 在更广泛的保健部门,外向投资激增,2025年9月结束的季度有72项交易,价值近35亿美元,比前一个季度增加166%。 The broader healthcare sector saw a surge in outbound investment, with 72 deals worth nearly $3.5 billion in the quarter ending September 2025—a 166% increase from the prior quarter.